Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 20/20 | 1.00 |
| ▸ | PIK3CG | P48736 | 13/20 | 1.00 |
| ▸ | PIK3R2 | O00459 | 11/20 | 1.00 |
| ▸ | PIK3CB | P42338 | 1/20 | 1.00 |
| ▸ | PIK3R1 | P27986 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amdizalisib SCHEMBL17633482 | 1.00 | PIK3CD (1.00) | PIK3CDPIK3CGPIK3R2PIK3CBPIK3R1 | |
| Amdizalisib SCHEMBL17640647 | 1.00 | PIK3CD (1.00) | PIK3CDPIK3CGPIK3R2PIK3CBPIK3R1 | |
| SCHEMBL17640787 | 0.92 | PIK3CD (1.00) | PIK3CDPIK3CGPIK3R2PIK3CBPIK3R1 | |
| SCHEMBL17640695 | 0.92 | PIK3CD (1.00) | PIK3CDPIK3CGPIK3R2PIK3CBPIK3R1 | |
| SCHEMBL17640694 | 0.91 | PIK3CD (1.00) | PIK3CDPIK3CGPIK3R2PIK3CBPIK3R1 | |
| SCHEMBL17640796 | 0.91 | PIK3CD (1.00) | PIK3CDPIK3CGPIK3R2PIK3CBPIK3R1 | |
| SCHEMBL17640791 | 0.91 | PIK3CD (1.00) | PIK3CDPIK3CGPIK3R2PIK3CBPIK3R1 | |
| SCHEMBL17640784 | 0.91 | PIK3CD (1.00) | PIK3CDPIK3CGPIK3R2PIK3CBPIK3R1 | |
| SCHEMBL19307586 | 0.91 | PIK3CD (1.00) | PIK3CDPIK3CGPIK3R2PIK3CBPIK3R1 | |
| SCHEMBL20964205 | 0.91 | PIK3CD (1.00) | PIK3CDPIK3CGPIK3R2PIK3CBPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12180214-B2 | Crystalline forms of (s)-4-amino-6-((1-(3-chloro-6-phenylimidazo[1,2-b]pyridazine-7-yl)ethyl)amino)pyrimidine-5-carbonitrile as inhibitors of phosphatidylinositol-3-kinase | HUTCHISON MEDIPHARMA LIMITED (CN) | 2024-12-31 | — | — | US | claimed |
| US-20230151015-A1 | THE CRYSTALLINE FORMS OF A COMPOUND | HUTCHISON MEDIPHARMA LIMITED (CN) | 2023-05-18 | — | — | US | claimed |
| US-11584750-B2 | Crystalline forms of (S)-4-amino-6-((1-(3-chloro-6-phenylimidazo[1,2-b]pyridazine-7-yl)ethyl)amino)pyrimidine-5-carbonitrile as inhibitors of phosphatidylinositol-3-kinase | HUTCHISON MEDIPHARMA LIMITED (CN) | 2023-02-21 | — | — | US | claimed |
| US-20210238180-A1 | THE CRYSTALLINE FORMS OF A COMPOUND | HUTCHISON MEDIPHARMA LIMITED (CN) | 2021-08-05 | — | — | US | claimed |
| CN-112074517-A | Crystal forms of a compound | 和记黄埔医药（上海）有限公司 | 2020-12-11 | — | — | CN | claimed |
| US-12180214-B2 | Crystalline forms of (s)-4-amino-6-((1-(3-chloro-6-phenylimidazo[1,2-b]pyridazine-7-yl)ethyl)amino)pyrimidine-5-carbonitrile as inhibitors of phosphatidylinositol-3-kinase | HUTCHISON MEDIPHARMA LIMITED (CN) | 2024-12-31 | — | — | US | disclosed |
| US-12180214-B2 | Crystalline forms of (s)-4-amino-6-((1-(3-chloro-6-phenylimidazo[1,2-b]pyridazine-7-yl)ethyl)amino)pyrimidine-5-carbonitrile as inhibitors of phosphatidylinositol-3-kinase | HUTCHISON MEDIPHARMA LIMITED (CN) | 2024-12-31 | — | — | US | disclosed |
| US-12180214-B2 | Crystalline forms of (s)-4-amino-6-((1-(3-chloro-6-phenylimidazo[1,2-b]pyridazine-7-yl)ethyl)amino)pyrimidine-5-carbonitrile as inhibitors of phosphatidylinositol-3-kinase | HUTCHISON MEDIPHARMA LIMITED (CN) | 2024-12-31 | — | — | US | disclosed |
| JP-2024040206-A | CRYSTALLINE FORMS OF COMPOUND | ハチソン メディファルマ リミテッド | 2024-03-25 | — | — | JP | disclosed |
| US-20230151015-A1 | THE CRYSTALLINE FORMS OF A COMPOUND | HUTCHISON MEDIPHARMA LIMITED (CN) | 2023-05-18 | — | — | US | disclosed |
| US-20230151015-A1 | THE CRYSTALLINE FORMS OF A COMPOUND | HUTCHISON MEDIPHARMA LIMITED (CN) | 2023-05-18 | — | — | US | disclosed |
| US-20230151015-A1 | THE CRYSTALLINE FORMS OF A COMPOUND | HUTCHISON MEDIPHARMA LIMITED (CN) | 2023-05-18 | — | — | US | disclosed |
| US-20190127391-A1 | NOVEL IMIDAZOPYRIDAZINE COMPOUNDS AND THEIR USE | HUTCHISON MEDIPHARMA LTD (CN) | 2019-05-02 | — | — | US | disclosed |
| US-10208066-B2 | Imidazopyridazine compounds and their use | HUTCHISON MEDIPHARMA LIMITED (CN) | 2019-02-19 | — | — | US | disclosed |
| US-10208066-B2 | Imidazopyridazine compounds and their use | HUTCHISON MEDIPHARMA LIMITED (CN) | 2019-02-19 | — | — | US | disclosed |
| US-20170253618-A1 | NOVEL IMIDAZOPYRIDAZINE COMPOUNDS AND THEIR USE | HUTCHISON MEDIPHARMA LIMITED (CN) | 2017-09-07 | — | — | US | disclosed |
| US-20170253618-A1 | NOVEL IMIDAZOPYRIDAZINE COMPOUNDS AND THEIR USE | HUTCHISON MEDIPHARMA LIMITED (CN) | 2017-09-07 | — | — | US | disclosed |
| EP-3197898-A1 | NOVEL IMIDAZOPYRIDAZINE COMPOUNDS AND THEIR USE | Hutchison Medipharma Limited (CN) | 2017-08-02 | — | — | EP | disclosed |
| WO-2016045591-A1 | NOVEL IMIDAZOPYRIDAZINE COMPOUNDS AND THEIR USE | HUTCHISON MEDIPHARMA LIMITED (CN) | 2016-03-31 | — | — | WO | disclosed |
| WO-2016045591-A1 | NOVEL IMIDAZOPYRIDAZINE COMPOUNDS AND THEIR USE | HUTCHISON MEDIPHARMA LIMITED (CN) | 2016-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238180-A1 | THE CRYSTALLINE FORMS OF A COMPOUND | CYP4B1, CYP3A5, CYP3A4 | PIK3CD 3498/4885PIK3CG 3255/4885PIK3R2 4834/4885 |
| US-20170253618-A1 | NOVEL IMIDAZOPYRIDAZINE COMPOUNDS AND THEIR USE | PIK3R5, PIK3CD, PIK3CB | PIK3CD 2/4885PIK3CG 9/4885PIK3R2 10/4885 |
| US-10208066-B2 | Imidazopyridazine compounds and their use | PIK3R5, PIK3CD, INPP5D | PIK3CD 2/4885PIK3CG 8/4885PIK3R2 9/4885 |
| US-12180214-B2 | Crystalline forms of (s)-4-amino-6-((1-(3-chloro-6-phenylimidazo[1,2-b]pyridazine-7-yl)ethyl)amino)pyrimidine-5-carbonitrile as inhibitors of phosphatidylinositol-3-kinase | PI4KA, PIK3CA, PI4K2B | PIK3CD 12/4885PIK3CG 16/4885PIK3R2 200/4885 |
| US-20190127391-A1 | NOVEL IMIDAZOPYRIDAZINE COMPOUNDS AND THEIR USE | PIK3R5, PIK3CD, PIK3CB | PIK3CD 2/4885PIK3CG 9/4885PIK3R2 10/4885 |
| US-11584750-B2 | Crystalline forms of (S)-4-amino-6-((1-(3-chloro-6-phenylimidazo[1,2-b]pyridazine-7-yl)ethyl)amino)pyrimidine-5-carbonitrile as inhibitors of phosphatidylinositol-3-kinase | PI4KA, PIK3CA, PI4K2B | PIK3CD 12/4885PIK3CG 16/4885PIK3R2 200/4885 |
| US-20230151015-A1 | THE CRYSTALLINE FORMS OF A COMPOUND | TYMP, TTR, TYMS | PIK3CD 3512/4885PIK3CG 2692/4885PIK3R2 4651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.